Research Article
[Retracted] Protumor Effects of Histone H3–H4 Chaperone Antisilencing Feature 1B Gene on Lung Adenocarcinoma: In Silico and In Vitro Analyses
Table 4
Logistic regression analysis outcomes showing the association of ASF1B expression with the clinical characteristics of LUAD patients.
| | Characteristics | Total () | Odds ratio (OR) | value |
| | T stage (T3&T4 vs. T1&T2) | 532 | 1.135 (0.682-1.896) | 0.627 | | N stage (N1&N2&N3 vs. N0) | 519 | 1.803 (1.245-2.624) | 0.002 | | M stage (M1 vs. M0) | 386 | 2.209 (0.957-5.533) | 0.073 | | Pathologic stage (stage III&stage IV vs. stage I&stage II) | 527 | 1.628 (1.065-2.507) | 0.025 | | Primary therapy outcome (PD&SD vs. PR&CR) | 446 | 1.614 (1.044-2.512) | 0.032 | | Gender (male vs. female) | 535 | 1.244 (0.886-1.750) | 0.208 | | Race (Asian&Black or African-American vs. White) | 468 | 1.071 (0.626-1.832) | 0.800 | | Age (>65 vs. ≤65) | 516 | 0.667 (0.471-0.943) | 0.022 | | Smoker (yes vs. no) | 521 | 0.883 (0.539-1.441) | 0.618 | | Residual tumor (R1&R2 vs. R0) | 372 | 1.647 (0.613-4.871) | 0.336 | | Anatomic neoplasm subdivision 2 (peripheral lung vs. central lung) | 189 | 1.352 (0.734-2.493) | 0.332 | | Number of pack years smoked (≥40 vs. <40) | 369 | 1.432 (0.951-2.161) | 0.086 |
|
|
